<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Summary of the clinical efficacy results for larotrectinib and entrectinib in a variety of tumor types with TRK fusions*&lt;SUP&gt;[1,2]&lt;/SUP&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Summary of the clinical efficacy results for larotrectinib and entrectinib in a variety of tumor types with TRK fusions*<sup>[1,2]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Summary of the clinical efficacy results for larotrectinib and entrectinib in a variety of tumor types with TRK fusions*<sup>[1,2]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup width="60%"></colgroup><colgroup span="2" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Larotrectinib<sup>[1]</sup></td> <td class="subtitle1">Entrectinib<sup>[2]</sup></td> </tr> <tr class="divider_bottom"> <td><strong>Design</strong></td> <td class="centered">Multiple studies</td> <td class="centered">Multiple studies</td> </tr> <tr class="divider_bottom"> <td><strong>Number</strong></td> <td class="centered">159</td> <td class="centered">54</td> </tr> <tr> <td colspan="3"><strong>Age group, n (%)</strong></td> </tr> <tr> <td class="indent1">&lt;18 years</td> <td class="centered">52 (33%)</td> <td class="centered">0<sup>¶</sup></td> </tr> <tr class="divider_bottom"> <td class="indent1">≥18 years</td> <td class="centered">107 (67%)</td> <td class="centered">54 (100%)</td> </tr> <tr class="divider_bottom"> <td><strong>Age, median</strong></td> <td class="centered">43 years</td> <td class="centered">57 years</td> </tr> <tr> <td colspan="3"><strong>Tumor types</strong></td> </tr> <tr> <td class="indent1">Sarcoma other than fibrosarcoma or GIST</td> <td class="centered">36 (23%)</td> <td class="centered">13 (24%)</td> </tr> <tr> <td class="indent1">Salivary</td> <td class="centered">21 (13%)</td> <td class="centered">7 (13%)</td> </tr> <tr> <td class="indent1">Infantile fibrosarcoma</td> <td class="centered">29 (18%)</td> <td class="centered">0 (0%)</td> </tr> <tr> <td class="indent1">Thyroid</td> <td class="centered">26 (16%)</td> <td class="centered">5 (9%)</td> </tr> <tr> <td class="indent1">Lung cancer</td> <td class="centered">12 (8%)</td> <td class="centered">10 (19%)</td> </tr> <tr> <td class="indent1">Melanoma</td> <td class="centered">7 (4%)</td> <td class="centered">0 (0%)</td> </tr> <tr> <td class="indent1">Colon</td> <td class="centered">8 (5%)</td> <td class="centered">4 (7%)</td> </tr> <tr> <td class="indent1">Cholangiocarcinoma</td> <td class="centered">2 (1%)</td> <td class="centered">1 (2%)</td> </tr> <tr> <td class="indent1">Pancreatic</td> <td class="centered">2 (1%)</td> <td class="centered">3 (6%)</td> </tr> <tr> <td class="indent1">Breast</td> <td class="centered">5 (3%)</td> <td class="centered">6 (11%)</td> </tr> <tr> <td class="indent1">Neuroendocrine</td> <td class="centered">0 (0%)</td> <td class="centered">3 (6%)</td> </tr> <tr> <td class="indent1">Gynecologic</td> <td class="centered">0 (0%)</td> <td class="centered">2 (4%)</td> </tr> <tr> <td class="indent1">Gastrointestinal stromal tumor</td> <td class="centered">3 (5%)</td> <td class="centered">0 (0%)</td> </tr> <tr class="divider_bottom"> <td class="indent1">Appendix</td> <td class="centered">1 (&lt;1%)</td> <td class="centered">0 (0%)</td> </tr> <tr> <td><strong>Overall response rate, % (95% CI)</strong></td> <td class="centered"><strong>79% (72 to 85)</strong></td> <td class="centered"><strong>57% (43 to 71)</strong></td> </tr> <tr> <td class="indent1">Complete response</td> <td class="centered">16%</td> <td class="centered">7%</td> </tr> <tr class="divider_bottom"> <td class="indent1">Partial response</td> <td class="centered">63%</td> <td class="centered">50%</td> </tr> <tr class="divider_bottom"> <td><strong>Intracranial response rate</strong></td> <td class="centered">NR<sup>Δ</sup></td> <td class="centered">71% (5 of 7)</td> </tr> <tr class="divider_bottom"> <td><strong>Duration of response, months (95% CI)</strong></td> <td class="centered">35.2 (22.8 to non-estimable)</td> <td class="centered">10.4 (7.1 to NE)</td> </tr> <tr class="divider_bottom"> <td><strong>Median follow-up time, months</strong></td> <td class="centered">12.9</td> <td class="centered">NR</td> </tr> <tr> <td colspan="3"><strong>Duration of response estimates</strong></td> </tr> <tr> <td class="indent1">9 months</td> <td class="centered">–</td> <td class="centered">59%</td> </tr> <tr> <td class="indent1">12 months</td> <td class="centered">80%</td> <td class="centered">–</td> </tr> </tbody></table></div><div class="graphic_footnotes">TRK: tropomyosin receptor kinase; NR: not reported; NE: not estimable.<br/>* All data presented reflect information from two clinical reports and from larotrectinib and entrectinib US Food and Drug Administration (FDA) prescribing information, unless otherwise stated.<br/>¶ Anecdotal adolescent cases published as case reports but not part of approval package.<br/>Δ Only 3 patients enrolled had measurable central nervous system metastasis at baseline; one had a complete response, and one a partial response.</div><div class="graphic_reference">References: 

<ol>
<li>Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 2020; 21:531.</li>
<li>Demetri GD, Paz-Ares L, Farago AF, et al. Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) tumors: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001. Ann Oncol 2018; 29:viii713.</li></ol></div><div id="graphicVersion">Graphic 126090 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
